A startling new study has delivered a crucial message for millions of people with type 2 diabetes. For those using a popular class of drugs, stopping the medication could dramatically increase the risk of a major cardiovascular event.
A Doubled Risk
A recent study has
found that people with type 2 diabetes who discontinue their GLP-1 receptor agonist medications face a doubled risk of suffering a non-fatal heart attack, a non-fatal stroke, or death from any cause compared to those who continue their treatment. The study, published in The Lancet Regional Health Europe, analysed the health records of over 80,000 people in Italy with type 2 diabetes. The findings translate to a significant real-world impact: among those who stopped the medication, there were roughly four major cardiovascular events per 100 people per year. For those who continued the treatment, that number was only two per 100 people. This highlights the profound protective benefits these medications offer and the potential dangers of halting them without a doctor's guidance.
Understanding GLP-1 Drugs
The medications at the centre of this study are GLP-1 receptor agonists. This class of drugs has become a cornerstone in managing type 2 diabetes and, more recently, has gained fame for its effectiveness in promoting weight loss. These drugs work by mimicking a natural hormone called GLP-1, which helps regulate blood sugar and reduce appetite. Beyond blood sugar control and weight loss, multiple studies have confirmed their significant benefits for heart and kidney health. The new research reinforces that these cardiovascular benefits are not a temporary fix but are dependent on continued use of the medication. The protective effect appears to fade quickly once the treatment is stopped.
Why Does the Risk Increase?
The study authors noted that after patients stopped treatment, their weight, blood sugar, and blood pressure changed only modestly, suggesting these factors may not be the sole explanation for the sharply increased cardiovascular risk. Other research provides further clues. A large study of U.S. veterans found that discontinuing GLP-1 drugs was associated with a progressive increase in risk; after two years off the medication, the risk of heart attack, stroke, and death was 22% higher than for continuous users. Experts suggest that stopping the medication may lead to a rebound in inflammation and other cardiometabolic risk factors that were being suppressed by the drug. It underscores that the benefits are tied directly to the ongoing presence of the medication in the body.
The Importance of Adherence
Despite their proven benefits, many patients stop taking these crucial medications, often within the first year. Reasons for discontinuation can range from side effects, such as gastrointestinal issues, to high costs and supply shortages. This research serves as a powerful reminder of the importance of medication adherence. Previous studies have consistently shown that good adherence to diabetes and cardiovascular medications is linked to a lower risk of hospitalisation and death. The findings from the latest studies on GLP-1 drugs add a new layer of urgency, demonstrating how quickly protective effects can be lost.
What Patients Should Do
This news should not be a cause for alarm, but for awareness and action. The clear message is not that the drugs are dangerous, but that their protective effects are so significant that stopping them can leave a person vulnerable. Anyone taking a GLP - 1 medication for type 2 diabetes should not stop or change their dosage without first consulting their doctor. If you are experiencing side effects, struggling with costs, or considering stopping for any other reason, it is vital to have an open conversation with your healthcare provider. They can discuss the risks and benefits, explore alternative treatments, or find solutions to help you stay on your prescribed therapy safely. The study is a call for better strategies to ensure patients can continue these life - saving treatments without interruption.
